



Chief Executive: Joe Harrison

Chair: Heidi Travis

## Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Monday 14<sup>th</sup> October 2024. I am pleased to confirm the following.

## Q1. How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib)- 2
- Amivantamab-0
- Atezolizumab Monotherapy- 4
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel-0
- Atezolizumab subcutaneous- 4
- Dabrafenib + Trametinib-0
- Docetaxel monotherapy or in combination with Carboplatin/Cisplatin-0
- Durvalumab-1
- Gemcitabine-1
- Nintedanib + Docetaxel- 2
- Nivolumab-0
- Osimertinib- 11
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)-0
- Paclitaxel-0
- Pembrolizumab Monotherapy-7
- Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin)-1
- Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)- 4
- Pemetrexed + Platinum (Carboplatin/Cisplatin)- 3
- RET Inhibitors (Pralsetinib, Selpercatinib)-0
- Sotorasib-0
- Tepotinib-0
- Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin-5
- Other active systemic anti-cancer therapy- CAV 1, Topotecan 1
- Palliative care only- no access to this information

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.